CRISPR Therapeutics CRSP Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's additional paid-in capital?
- CRISPR Therapeutics (CRSP) reported additional paid-in capital of $3.88B in Q1 2026.
- How has CRISPR Therapeutics's additional paid-in capital changed year-over-year?
- CRISPR Therapeutics's additional paid-in capital increased by 16.8% year-over-year, from $3.32B to $3.88B.
- What is the long-term trend for CRISPR Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's additional paid-in capital has grown at a 11.6% compound annual growth rate (CAGR), from $2.24B to $3.86B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.